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DNA oligonucleotide microarray technology identifies fisp-12
among other potential fibrogenic genes following murine unilat-
eral ureteral obstruction (UUO): Modulation during epithelial-
mesenchymal transition.
Background. Tubulointerstitial inflammation and fibrosis are
pathologic hallmarks of end-stage renal disease (ESRD). Here
we have used DNA microarray technology to monitor the tran-
scriptomic responses to murine unilateral ureteral obstruction
(UUO) with a view to identifying molecular modulators of tubu-
lointerstitial fibrosis.
Methods. Using Affymetrix Mu74Av2 microarrays, gene
expression 4 and 10 days postobstruction was investigated rel-
ative to control contralateral kidneys. Candidate profibrogenic
genes were further investigated in epithelial cells undergoing
epithelial to mesenchymal transition (EMT) in vitro.
Results. mRNA levels for 1091 gene/EST sequences, of
a total of 12,488 displayed on the microarray, were altered
twofold or greater by days 4 and 10 postobstruction compared
to contralateral control kidneys. Genes were categorised into
functional groups, including modulators of cytoskeletal and
extracellular matrix metabolism, cell growth, signalling, and
transcription/translational events. Among the potentially profi-
brogenic genes, whose mRNA levels were increased after UUO,
were fibroblast-inducible secreted protein (fisp-12), the murine
homologue of connective tissue growth factor (CTGF), collagen
XVIIIa1, secreted protein acidic and rich in cysteine (SPARC),
and src-suppressed C-kinase substrate (SSeCKS). A sustained
increase in fisp-12 mRNA level was observed during EMT in-
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duced by transforming growth factor-b1 (TGF-b1) and epider-
mal growth factor (EGF).
Conclusion. Altered gene expression in murine UUO has
been demonstrated. Increased expression of fisp-12, SPARC,
and SSeCKS has been shown in response to TGF-b1 treatment
and during EMT, suggesting that these genes may offer potential
therapeutic targets against tubulointerstitial fibrosis.
Tubulointerstitial inflammation and fibrosis are patho-
logic hallmarks of end-stage renal disease (ESRD). Renal
tubulointerstitial fibrosis develops regardless of the initi-
ating insult and the extent of fibrosis correlates with the
loss of renal function [1, 2]. Chronic unilateral ureteral
obstruction (UUO) is a well-characterized model of tubu-
lointerstitial fibrosis [3] and promotes interstitial extra-
cellular matrix accumulation with tubular epithelial cell
atrophy and apoptosis [4]. Pathologic roles for trans-
forming growth factor-b1 (TGF-b1) [5], vascular cell
adhesion molecule-1 (VCAM-1) [6], intercellular adhe-
sion molecule-1 (ICAM-1) [6, 7], heat shock protein 47
(HSP47) [8], and Smad 7 [9] among other mediators of
tubulointerstitial damage have been demonstrated us-
ing this model. We have exploited this in vivo model
to investigate the transcriptomic responses implicated
in the pathology of renal fibrosis by oligonucleotide
microarrays.
During UUO, a number of changes occur in the
obstructed kidney that culminate in the progression of
tubulointerstitial fibrosis. In the mouse UUO model,
increased numbers of inflammatory cells are observed in
the tubulointerstitium as early as day 4, tubular epithe-
lial cells initially proliferate and then undergo apoptosis
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leading to loss of epithelial integrity [4]. Tubular lumens
undergo dilatation and tubular epithelial cells become
flattened. Increased numbers of fibroblasts are observed
in the interstitium, which are postulated to derive from
(1) proliferation of resident fibroblast populations, (2)
recruitment of fibrocytes from the circulation, and (3)
transition of tubular epithelial cells toward a fibroblast
phenotype. Extracellular matrix molecules accumulate
in the interstitial compartment and by day 10 postob-
struction the degree of fibrosis in the murine kidney is
extensive. In the present study, Affymetrix Mu74Av2
arrays, representing over 12,000 murine sequences, were
employed to analyze gene expression at days 4 and 10 pos-
tobstruction. Day 4 post-UUO was chosen to represent
an early time point in the development of tubulointer-
stitial fibrosis where changes in inflammatory genes and
associated growth factor populations would be detected.
Day 10 post-UUO, dominated by fibrotic tissue, was stud-
ied to identify genes whose expression remains altered
in a fibrotic environment. We predicted that over the
course of ureteral ligation, we would observe an increase
in profibrotic genes, a decrease in epithelial cell growth
regulators, an increase in proinflammatory and apoptosis-
related genes, and potentially a change in gene expres-
sion corresponding to epithelial-mesenchymal transition
(EMT) and myofibroblastic proliferation.
Gene expression in UUO kidneys was compared to
that of contralateral unobstructed kidneys. Although
contralateral kidneys respond to UUO of the ipsilateral
kidney by increasing glomerular filtration rates, changes
observed in the gene expression of the contralateral
kidney more closely parallel that of age-matched con-
trol sham-operated kidneys [10, 11]. Indeed, tubular and
interstitial cell proliferation and apoptotic rates in the
contralateral kidney are similar to that of sham-operated
control kidneys [12]. Furthermore, contralateral kidneys
at day 10 postobstruction do not display any histomor-
phologic damage [13]. Therefore, in our experiments,
baseline gene expression was taken as the expression
level observed in the contralateral kidney.
Transcripts differentially expressed in obstructed kid-
neys included (1) genes whose expression had been re-
ported previously in UUO and tubulointerstitial fibrosis
and which serve to validate the approach, (2) genes not
implicated in the pathogenesis of tubulointerstitial fibro-
sis heretofore, but whose profile of biologic activity else-
where suggests a novel role, and (3) unannotated genes.
Among the genes up-regulated in response to UUO
was fibroblast-inducible secreted protein (fisp-12), the
murine homologue of human connective tissue growth
factor (CTGF) [14]. Recent evidence suggests that this
gene may play an important role in the development of
tubulointerstitial fibrosis [15]. We have further examined
the expression of this gene in proximal tubular epithelial
cells in vitro in response to TGF-b1 stimulation, which
induces EMT, a process that recently has been deter-
mined to contribute significantly to renal fibrosis [16].
CTGF has been recognized as a down-stream mediator
of TGF-b1 signaling [17] and has been shown to induce
collagen deposition in several renal cell lines, including
mesangial cells and interstitial fibroblasts. Here, we
report the production of CTGF by proximal tubular
epithelial cells, further highlighting the pathophysiologic
potential of this gene in renal fibrosis.
Cytokines and growth factors are important stimuli
for renal fibrosis due to EMT within diseased kidneys
[18] and approximately one third of fibroblasts in fibrotic
kidneys appear to be derived from EMT of tubular ep-
ithelial cells [16]. During EMT, tubular cells lose their
epithelial cell markers, including cytokeratin, and express
increased levels of fibroblast markers, including vimentin,
and fibroblast-specific protein 1 (fsp-1) [19]. Collagen I
deposition has been associated with myofibroblast cells in
areas of tubulointerstitial fibrosis, and the origin of these
myofibroblasts has been linked to transition of tubular
epithelial cells [18–20]. In order to further investigate the
role of EMT in tubulointerstitial fibrosis, we performed
in vitro studies on proximal tubular epithelial cells stimu-
lated with TGF-b1. Interestingly, we found that a number
of the genes identified in our microarray screen were also
responsive to TGF-b1 treatment, highlighting the impor-
tance of this growth factor in the progression of fibrosis.
We further analyzed the expression of secreted protein
acidic and rich in cysteine (SPARC), src-suppressed
C-kinase substrate (SSeCKS), and collagen XVIIIa1 dur-
ing EMT since these were identified in our microarray
screens and are suggested in the literature to play a role
in the control of cytoskeletal structure, which undergoes
marked changes during the EMT process.
In summary, this report details our findings of global
gene expression changes occurring during the develop-
ment of tubulointerstitial fibrosis. Our screen identified
over 1000 genes whose expression was altered in response
to UUO and involved the identification of genes already
associated with fibrosis along with novel associations. Of
the genes identified, we further analyzed fisp-12 (CTGF),
collagen XVIIIa1, SSeCKS, and SPARC expression in
vitro in response to TGF-b1 stimulation and have shown
that these genes act downstream of this cytokine and
therefore may play important roles in the progression
of renal fibrosis. Our microarray data, available online
at http://www.ucd.ie/conway/offers valuable information
into the changes which occur in gene expression during
the process of tubulointerstitial fibrosis.
METHODS
Unilateral ureteral obstruction
Obstructed (N = 4 day 4, N = 4 day 10) and contralat-
eral control kidneys (N = 4 day 4, N = 4 day 10) were
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prepared as follows. C57BL/6 mice of 12 ± 2 weeks of age
were kept in macrolone type III cages under a 12-hour
light and dark cycle, water and standard chow (Sniff,
Soest, Germany) were available ad libitum. Ureteric
obstruction was performed under general anesthesia by
ligating the left ureter with 4-0 mersilene through a
midline abdominal incision [13]. Mice were sacrificed
either 4 days or 10 days post-UUO by cervical dislocation
under general anesthesia with inhaled ether. Contralat-
eral kidneys were used as intraindividual nonobstructed
controls. Histologic examination of the obstructed kid-
neys revealed a macrophage and lymphocytic cell
infiltrate in the tubulointerstitium, interstitial fibrosis,
tubular dilation, and tubular cell flattening with necro-
sis/apoptosis progressing from day 4 to day 10. All ani-
mal experiments were carried out in accordance with the
ethical guidelines of the Ludwig Maximilians University.
Cell culture and EMT
Murine proximal tubular (MCT) epithelial cells [21]
were grown in Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F12 medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal calf serum
(FCS), 1% glutamine, 1% penicillin, and 1% strepto-
mycin. For experiments, cells were serum starved in K-1
medium: DMEM/Ham’s F12 medium supplemented with
1% glutamine, 1% penicillin, and 1% streptomycin,
5 lg/mL insulin, 5 lg/mL transferrin, 5 ng/mL selenium,
and 36 ng/mL hydrocortisone [18]. To investigate the
potential of TGF-b1 to drive the expression of fisp-12,
5 × 104 MCT cells were plated onto 6-well plates (Costar
Cambridge, MA, USA), grown for 48 hours at 37◦C in
the presence of 5% CO2, serum starved for 24 hours and
treated with either 3 or 10 ng/mL TGF-b1 for 24 hours.
MCT cells were induced to undergo EMT according to
the protocol of Strutz et al [19] using 3 ng/mL TGF-b1
and 10 ng/mL EGF for 72 hours.
RNA isolation and semiquantitiative reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from obstructed and con-
tralateral murine kidneys and MCT epithelial cells using
TRizol LS reagent (Invitrogen) as per manufacturer’s
instructions. Two micrograms total RNA was DNase-
treated with 1 U DNase I (Invitrogen) for 15 minutes
at room temperature in a 10 lL reaction. The DNase was
inactivated by the addition of 1 lL of 25 mmol/L ethylene-
diaminetetraacetic acid (EDTA) at 65◦C for 10 minutes.
DNase-treated total RNA was reverse-transcribed in a
20 lL reaction containing 50 mmol/L Tris-HCl, pH 8.3,
75 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L dithio-
threitol (DTT), 500 lmol/L desoxynucleoside triphos-
phate (dNTP), 100 ng of random hexamers (Invitrogen).
Two hundred units of Superscript II RNase H− reverse
transcriptase were added and the reactions incubated at
42◦C for 1 hour. One microliter of each RT reaction was
PCR amplified in a 50 lL reaction containing 20 mmol/L
Tris-HCl, pH 8.4, 50 mmol/L KCl, 1.5 mmol/L MgCl2,
200 mmol/L dNTP, and 100 ng of forward (F) and re-
verse (R) primers: epidermal growth factor (EGF)-F, 5′-
CGG AAG TAC TGC GAA GAT GTC, EGF-R, 5′-
TAG ATT CTC CGG CCA ATC CA, 658 bp product;
ColIa1-F, 5′-ATG TTC AGC TTT GTG GAC CTC CG,
ColIa1-R, 5′-TCA TAG CCA TAG GAC ATC TGG G,
473 bp product; transgelin-F, 5′-CTG AGC AAR TTG
GTG AAC AGC, transgelin-R, 5′-CCA TGT GCA GTC
ATC TTT GC, 541 bp product; fisp12-F, 5′-CTA AGA
CCT GTG GAA TGG GC, fisp12-R, 5′-CTC AAA GAT
GTC ATT GTC CCC, 386 bp product; Col8a1-F, 5′-AYT
TCC CAG TGC TTC CAG CAA G, Col8a1-R, 5′-TTG
GAG AAA GAG GTC ATG AAG C, 460 bp product;
fsp1-F, 5′-CCA CCT TCC ACA ART ACT CRG G, fsp1-
R, 5′-TCW GAG GAG TYT TCA YTT CTT CC, 470 bp
product; SPARC-F, 5′-GCA ATG ACA ACA AGA CCT
TCG, SPARC-R, 5′-TTG TCS TTG TCT AGG TCA
CAG G, 498 bp product; SSeCKS-F, 5′-TGA AGC AAT
CCA CAG AGA AGC, SSeCKS-R, 5′-CTC ATC AAA
CAC TTC CGT TGC, 499 bp product; glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)-F, 5′-ACC ACA
GTC CAT GCC ATC, GAPDH-R, 5′-TCC ACC ACC
CTG TTG CTG, 452 bp product; 18S-F, GTG GAG CGA
TTT GTC TGG TT and 18S-R, CGC TGA GCC AGT
CAG TGT AG, 200 bp product. PCR amplification was
typically performed at 25 to 30 cycles of 94◦C, 57◦C, and
72◦C for 30 seconds each followed by a final 3-minute
extension at 72◦C. RT-PCR products were resolved
on 1% agarose gels and visualized by ethidium bro-
mide staining. All samples were quantitated using image
software Grabit and Gelworks (Ultra-Violet Products,
Cambridge, UK) and were normalized to their respec-
tive 18S rRNA products.
Quantitative real-time PCR
Two micrograms of total RNA was reverse-transcribed
using random hexamers as described above. Quanti-
tative real-time PCR was performed using TaqMan
universal PCR master mix (P/N 4304437, Applied Biosys-
tems, Weiterstadt, Germany) as per manufacturer’s pro-
tocol. Samples were run in duplicate and were analyzed
using the ABI Prism 7700 Sequence Detection System
(Applied Biosystems). Probes, labeled with FAM, and
primers were designed using Primer Express (Applied
Biosystems): TGF-b1 probe, AGC GCA TCG AAG
CCA TCC GTG, TGF-b1 forward, TCG ACA TGG
AGC TGG TGA AA, TGF-b1 reverse, TGG CGA GCC
TTA GTT TGG A; fisp-12 probe, CCC CCG CCA ACC
GCA AGA TT, fisp-12 forward, CCC ACA CAA GGG
CCT CTT C, fisp-12 reverse, CCA TCT TTG GCA GTG
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CAC AC. TaqMan PCR reactions were multiplexed for
the gene of interest and VIC- labeled 18S rRNA, as an en-
dogenous control (P/N 4310893E, Applied Biosystems).
Affymetrix oligonucleotide microarray analysis
Total RNA was isolated from obstructed and contralat-
eral kidneys (N = 4 for treated and control at each
time point) and purified through an RNeasy minicolumn
(Qiagen, Valencia, CA, USA). Five micrograms of RNA
from each treatment were pooled. Five micrograms of
the pooled RNA was reverse-transcribed as above in a
20 lL reaction. Second-strand cDNA was synthesized by
adding 1× second-strand buffer [20 mmol/L Tris-HCl, pH
6.9, 4.6 mmol/L MgCl2, 90 mmol/L KCl, 150 mmol/L
b-NAD+, and 10 mmol/L (NH4)2SO4 final concentra-
tion], 200 mmol/L dNTP, 10 U DNA Ligase, 40 U DNA
polymerase I, and 2 U RNase H to the first-strand re-
action to a final volume of 150 lL. Samples were incu-
bated at 16◦C for 2 hours. Ten units T4 DNA polymerase
was added at 16◦C for 5 minutes followed by 10 lL of
0.5 mol/L EDTA. The double-stranded cDNA was
phenol-chloroform extracted and precipitated with 0.75
volumes of 5 mol/L NH4OH acetate and 2.5 volumes
of ice-cold absolute ethanol. The cDNA was pelleted
at 12,000 × g for 20 minutes at 4◦C, washed twice with
500 lL of ice-cold 75% ethanol in diethyl pyrocarbon-
ate (DEPC)-treated water and resuspended in 12 lL of
DEPC water. Ten microliters of double-stranded cDNA
was used as a template for the production of biotin-
labeled cRNA using the Bioarray High-Yield RNA Tran-
script Labeling Kit (Enzo, Farmingdale, NY, USA) as per
manufacturer’s instructions. cRNA was fragmented in 1×
fragmentation buffer (40 mmol/L Tris-acetate, pH 8.1, 100
mmol/L KO acetate, 30 mmol/L MgO acetate) at 94◦C
for 35 minutes. Fifteen micrograms of fragmented cRNA
was hybridized to the Mu74Av2 array as per Affymetrix
protocol. Arrays were washed and fluorescently labeled
prior to scanning with a confocal scanner (Affymetrix).
cRNA from freshly pooled RNA was prepared as above
and hybridized to a second set of arrays (as duplicate
experiments). Affymetrix Microarray Suite 5.0 was used
to scan and analyze the arrays, expression analysis was
performed using this software. Criteria for the selection of
genes included (1) presence on duplicate oligonucleotide
microarrays (with a similar Affymetrix flag call on straight
and cross-comparisons of the duplicate arrays of treated
kidneys to respective controls) and (2) those which dis-
played a greater than twofold average change in expres-
sion for at least one of the time points [an average for the
straight and cross comparisons of the duplicate arrays
(i.e., four comparisons for each time point) was calcu-
lated]. Microarray data in tables are shown as mean sig-
nal log ratio (where 1 is equivalent to a twofold change
in expression) ± standard deviation from the mean.
Statistical analysis
Data for gene chip analysis are expressed as mean ±
standard deviation. For the RT and the real time-PCR
analysis, data are expressed as mean ± SEM. Statistical
analysis was performed using a Student t test, a P value
<0.05 was considered statistically significant.
RESULTS
Increased mRNA levels for fisp-12, among other
profibrotic genes, following UUO as identified
by oligonucleotide microarrays
Alterations of gene expression in response to UUO
were analyzed using the Affymetrix Mu74Av2 oligonu-
cleotide microarray, representing approximately 6000
known gene sequences and 6000 EST sequences. Genes
were compared and selected as described in the Methods
section, using duplicate arrays each analyzing mRNA
pooled from four individual animals and using a twofold
change in gene expression as a cutoff point (signal log
ratio of 1 is equivalent to twofold up-regulation in gene
expression, −1 equivalent to a twofold down-regulation,
and 0 equivalent to no change). A total of 1091 gene/EST
sequences passed the selection criteria. Of these
sequences, 606 (55.5%) were up-regulated, 430 of which
represented annotated genes with the remainder rep-
resenting ESTs, and 485 (44.5%) were down-regulated
sequences, 251 representing annotated genes.
Murine kidneys subjected to UUO for 4 days (N = 4)
or 10 days (N = 4) were compared to their respective un-
obstructed contralateral kidneys as control (N = 4 at each
time point). Genes differentially expressed in response to
UUO included those encoding extracellular matrix and
cytoskeletal molecules (64 induced and seven repressed),
cell growth and differentiation related-molecules (47 in-
duced and five repressed), cytokines and growth fac-
tors (35 induced and seven repressed) (see Tables 1 to
3), signaling molecules (58 induced and 17 repressed),
and those involved with mRNA expression and trans-
lation (51 induced and 13 repressed). A complete list
of gene expression findings is available for download at
http://www.ucd.ie/conway/
Genes were analyzed on the basis of their temporal
expression pattern. Interestingly, the majority of genes,
which were differentially regulated in response to UUO
by day 4, were further increased or decreased by day
10 (Table 1). A small number of genes were identified
that showed a change in expression level by day 4 but
displayed a “no change” call by day 10 postobstruction
(Table 2). Furthermore, we identified a small number of
genes that displayed a “no change” call by day 4 pos-
tobstruction but were either up- or down-regulated by
day 10 (Table 3). Of note, this group included plasmino-
gen activator inhibitor (PAI-1), which has been shown
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Table 1. Genes whose expression is altered at both days 4 and 10 post unilateral ureteral obstruction (UUO)
Mean signal log ratioa
GenBank ID Gene family Day 4 ± SD Day 10 ± SD
Extracellular matrix and cytoskeletal
X66405 Procollagen, type VI, alpha 1 0.33 ± 0.24 1.05 ± 0.07
U03184 Cortactin 0.38 ± 0.40 1.25 ± 0.49
M63801 Connexin 43 (alpha-1 gap junction) 0.50 ± 0.37 1.60 ± 0.57
X98475 VASP gene 0.58 ± 0.05 1.20 ± 0.57
AF022432 MMP-14 0.58 ± 0.13 1.45 ± 0.21
L00923 Myosin I 0.58 ± 0.19 1.45 ± 0.49
D14340 Tight junction protein 1 0.65 ± 0.17 1.00 ± 0.28
U43327 Laminin, gamma 2 0.65 ± 0.10 1.50 ± 0.28
M13441 Alpha-tubulin isotype M-alpha-6 0.68 ± 0.10 1.05 ± 0.07
L23769 Microfibril-associated glycoprotein 0.68 ± 0.35 1.15 ± 0.21
M28727 Tubulin alpha 2 0.73 ± 0.13 1.00 ± 0.14
M84683 Tumor-associated mucin 1 0.75 ± 0.13 1.30 ± 0.00
U66166 Extracellular matrix protein 2 0.93 ± 0.28 2.00 ± 0.00
Y11460 Beta 4 integrin interactor, partial 0.98 ± 0.10 1.00 ± 0.14
M28729 Tubulin alpha 1 1.00 ± 0.24 1.85 ± 0.07
M28739 Tubulin, beta 2 1.03 ± 0.10 0.90 ± 0.00
D17546 Procollagen, type XV 1.05 ± 0.19 1.30 ± 0.00
X04647 Procollagen, type IV, alpha 2 1.05 ± 0.17 1.55 ± 0.21
M28729 Tubulin alpha 1 1.08 ± 0.05 1.20 ± 0.00
L17324 Nidogen 1.08 ± 0.15 1.40 ± 0.14
X15662 Cytokeratin endo A 1.23 ± 0.10 1.65 ± 0.07
X04663 Beta-tubulin (isotype M beta 5) 1.23 ± 0.44 1.85 ± 0.21
X56304 Tenascin C 1.23 ± 0.40 2.15 ± 0.35
J03520 Plasminogen activator, tissue 1.25 ± 0.17 1.30 ± 0.28
X60676 HSP47 1.33 ± 0.15 1.75 ± 0.07
X04663 Beta-tubulin (isotype M beta 5) 1.35 ± 0.10 2.05 ± 0.07
AI853217b Vascular epithelium cadherin 1.40 ± 0.64 1.20 ± 0.28
U04354 ADSEVERIN 1.40 ± 0.32 1.65 ± 0.07
X52490 Beta2 microglobulin 1.45 ± 0.13 1.55 ± 0.07
X01838 Beta2 microglobulin 1.55 ± 0.13 0.70 ± 0.00
X13297 Vascular smooth muscle alpha-actin 1.55 ± 0.37 1.80 ± 0.00
Z68618 Trasngelin 1.60 ± 0.12 1.75 ± 0.21
L02918 Procollagen type V alpha 2 (Col5a-2) 1.60 ± 0.54 2.00 ± 0.28
M22479 Tropomyosin isoform 2 1.60 ± 0.26 2.00 ± 0.00
Z19543 h2-calponin cDNA 1.65 ± 0.45 1.65 ± 0.21
M22832 Cytokeratin endoB 1.68 ± 0.38 2.25 ± 0.21
X04017 Cysteine-rich glycoprotein SPARC 1.75 ± 0.13 2.30 ± 0.14
X54511 Myc basic motif homologue-1, mbh1 1.78 ± 0.10 1.35 ± 0.07
U72519 Ena-VASP like protein (Evl) 1.80 ± 1.16 2.15 ± 0.07
AB000713 mCPE-R CPE-receptor 1.83 ± 0.73 2.40 ± 0.14
U38967 Prothymosin beta 4 1.80 ± 0.18 1.90 ± 0.14
M15832 Procollagen, type IV, alpha 1 1.93 ± 0.37 1.55 ± 0.35
AA763466b Collagen, alpha 1 type 1 1.93 ± 0.10 2.10 ± 0.28
L22545 Procollagen, type XVIII, alpha 1 2.00 ± 0.08 1.55 ± 0.07
U03715 Procollagen, type XVIII, alpha 1 2.25 ± 0.17 1.80 ± 0.28
L29454 Fibrillin 1 2.28 ± 0.72 2.30 ± 1.13
X58251 Procollagen, type I, alpha 2 2.28 ± 0.22 3.10 ± 0.14
AF064749 Type VI collagen alpha 3 subunit 2.68 ± 0.94 2.40 ± 0.14
AF011450 Procollagen, type XV 2.73 ± 0.21 2.30 ± 0.00
AV234303∗ Collagen, alpha 1 type III 2.78 ± 0.77 4.00 ± 0.14
AB020886 SSeCKS 2.88 ± 1.31 2.90 ± 0.42
X52046 Procollagen, type III, alpha 1 2.88 ± 0.38 3.65 ± 0.07
M36120 Keratin complex 1, acidic, gene 19 2.90 ± 0.16 6.00 ± 1.41
U03419 Alpha-1 type I procollagen 3.20 ± 0.16 3.70 ± 0.00
D49691 p50b (identical to LSP 1 and pp52) 4.10 ± 0.57 3.15 ± 0.78
M81445 Gap junction membrane channel protein beta 2 −0.70 ± 0.22 −1.95 ± 0.07
M18775 Microtubule-associated protein tau −0.60 ± 0.41 −1.70 ± 0.57
M18775 Microtubule-associated protein tau −0.55 ± 0.25 −1.30 ± 0.28
U26437 Tissue inhibitor of metalloproteinases-3 (TIMP-3) −0.55 ± 0.13 −1.20 ± 0.14
D78646 Zeta-crystallin −0.45 ± 0.06 −1.20 ± 0.14
L40632 Ankyrin 3, epithelial −0.38 ± 0.34 −1.00 ± 0.14
Cell growth and differentiation
U44088 TDAG51 (TDAG51) 0.45 ± 0.24 1.10 ± 0.28
L01640 D-type G1 cyclin catalytic subunit, PSK-J3 0.63 ± 0.05 1.00 ± 0.14
AF035939 Mago-nashi homolog 0.70 ± 0.22 1.00 ± 0.14
AF027707 Apoptosis activator Mtd (Mtd) 0.70 ± 0.36 1.20 ± 0.42
M73748 OTS-8 0.70 ± 0.18 2.25 ± 0.21
U96635 Developmentally down-regulated gene 4 0.75 ± 0.13 1.10 ± 0.14
U60530 MAD homolog 2, (Drosophila) 0.75 ± 0.33 1.30 ± 0.14
X65687 Thymoma viral proto-oncogene 0.78 ± 0.13 1.00 ± 0.00
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Table 1. (Continued)
Mean signal log ratioa
GenBank ID Gene family Day 4 ± SD Day 10 ± SD
J04103 E26 avian leukemia oncogene 2, 3 domain 0.80 ± 0.26 1.00 ± 0.00
X56602 lnterferon-induced 15-kD protein 0.88 ± 0.43 2.10 ± 1.27
AJ001616 Myeloid associated differentiation protein 0.90 ± 0.18 1.15 ± 0.21
V00755 Interferon beta, fibroblast 0.90 ± 0.27 1.35 ± 0.21
V00727 FBJ osteosarcoma oncogene 0.93 ± 0.50 2.55 ± 2.47
X57796 Tumor necrosis factor receptor 1a 1.00 ± 0.12 0.90 ± 0.14
AJ223782 CDC10 1.08 ± 0.30 1.30 ± 0.28
AB021961 Mutant p53 1.10 ± 0.58 1.00 ± 0.21
U58992 MAD homolog 1 (Drosophila) 1.13 ± 0.25 1.30 ± 0.35
D78354 TRA1 1.15 ± 0.19 0.70 ± 0.14
Z16410 btg1 1.30 ± 0.18 1.15 ± 0.07
U00937 GADD45 protein (gadd45) gene 1.30 ± 0.18 1.45 ± 0.21
M21065 Interferon regulatory factor 1 1.45 ± 0.86 1.15 ± 0.07
U92565 Small inducible cytokine subfamily D, 1 1.45 ± 0.10 1.65 ± 0.07
U88909 Apoptosis inhibitor 2 1.53 ± 0.15 1.15 ± 0.07
X78989 Testin 1.55 ± 0.13 1.45 ± 0.07
D87661 14-3-3 eta 1.60 ± 0.08 1.25 ± 0.07
U15635 IFN-gamma induced (Mg11) 1.60 ± 0.42 2.55 ± 1.20
M21019 Harvey rat sarcoma oncogene, subgroup R 1.63 ± 0.73 1.55 ± 0.49
M28233 Interferon-gamma receptor 1.78 ± 0.67 1.45 ± 0.64
AB015978 Oncostatin receptor 1.78 ± 0.22 2.55 ± 0.07
AF058798 14-3-3 protein sigma 1.93 ± 0.85 2.50 ± 0.14
AB007599 MD-1 2.33 ± 0.26 2.80 ± 0.42
AA790307∗ Onzin 2.48 ± 0.17 2.45 ± 0.07
AJ007970 mGBP-2 protein 2.58 ± 0.21 2.60 ± 0.00
U43085 Interferon-induced, tetratricopeptide repeats 2 2.75 ± 1.28 2.30 ± 0.57
L00039 Myelocytomatosis oncogene 2.83 ± 1.14 2.65 ± 0.78
U49513 Small inducible cytokine A9 3.30 ± 1.33 3.25 ± 0.92
J04596 GRO1 oncogene 4.25 ± 0.44 4.10 ± 0.28
X81627 24p3 gene 4.45 ± 0.47 5.75 ± 0.21
J04596 GRO1 oncogene 4.55 ± 0.90 3.65 ± 1.34
M19681 Small inducible cytokine A2 5.28 ± 0.63 4.85 ± 1.06
M21828 Growth arrest specific 2 −0.88 ± 0.10 −1.70 ± 0.00
AF100927 Apoptosis-inducing factor AIF −0.78 ± 0.13 −1.25 ± 0.21
AF041377 Cell death activator CIDE-B −0.65 ± 0.10 −1.40 ± 0.00
M31680 Growth hormone receptor −0.65 ± 0.78 −1.35 ± 0.64
U18869 Mitogen-responsive 96 kDa phosphoprotein p96 −0.50 ± 0.08 −1.05 ± 0.07
Cytokine and growth factor
M29464 Platelet derived growth factor, alpha 0.55 ± 0.06 1.10 ± 0.14
D16195 Granulin 0.73 ± 0.05 1.10 ± 0.14
X04367 Platelet derived growth factor receptor, beta 0.78 ± 0.22 1.30 ± 0.42
AF020185 Protein inhibitor of nitric oxide synthase (PIN) 0.95 ± 0.13 1.00 ± 0.00
M70642 Fibroblast inducible secreted protein (fisp-12) 1.10 ± 0.24 1.45 ± 0.07
M59821 Growth factor-inducible protein (pip92) 1.10 ± 0.23 1.75 ± 0.07
AF099973 Schlafen2 (Slfn2) 1.15 ± 0.47 1.45 ± 0.07
L03529 Thrombin receptor 1.18 ± 0.49 1.35 ± 0.21
M28845 Early growth response 1 1.18 ± 1.09 1.65 ± 0.07
U90123 Hematological and neurological expressed 1 1.28 ± 0.74 1.50 ± 0.00
U23778 Hematopoietic-specific early-response A1-b 1.38 ± 0.28 2.75 ± 0.35
U41341 Endothelial monocyte-activating polypeptide I 1.48 ± 0.13 1.45 ± 0.07
M27960 Interleukin-4 receptor (secreted form) 1.58 ± 1.26 1.70 ± 0.57
U23781 Hematopoietic-specific early-response A1-d 1.58 ± 0.25 2.25 ± 0.07
L19932 TGF, beta induced, 68 kDa 1.60 ± 0.68 1.75 ± 0.07
M32490 Insulin-like growth factor binding protein 10 1.60 ± 0.36 1.95 ± 0.35
X62940 TGF beta 1 induced transcript 4 1.63 ± 0.10 1.65 ± 0.07
M91380 Follistatin-like 1.75 ± 0.42 2.15 ± 0.21
AF099973 Schlafen2 (Slfn2) 1.78 ± 0.22 2.35 ± 0.07
M57683 Platelet derived growth factor receptor, alpha 1.80 ± 1.34 1.55 ± 0.21
M62470 Thrombospondin 1 1.85 ± 0.24 2.10 ± 0.14
AJ009862 Transforming growth factor-beta 1 2.15 ± 0.87 3.95 ± 0.35
M26071 Coagulation factor III 2.28 ± 0.38 2.80 ± 0.14
L31958 pMAT1 2.93 ± 0.46 3.60 ± 0.14
AF065947 Small inducible cytokine A5 4.03 ± 0.80 3.40 ± 0.28
V00741 Epidermal growth factor −3.03 ± 0.05 −5.00 ± 0.14
M17979 Epidermal growth factor binding protein type A −2.68 ± 0.17 −3.20 ± 0.28
M17962 Epidermal growth factor binding protein type C −2.55 ± 0.10 −2.75 ± 0.35
L12447 Insulin-like growth factor binding protein 5 −123 ± 0.05 −0.45 ± 0.07
X76066 Insulin like growth factor binding protein 4 −1.00 ± 0.08 −0.85 ± 0.07
U15012 Growth hormone receptor −0.78 ± 0.17 −1.95 ± 0.21
M30641 Fibroblast growth factor 1 −0.58 ± 0.26 −1.15 ± 0.35
Affymetrix oligonucleotide gene expression analysis of obstructed kidneys (N = 4) compared to contralateral control kidneys (N = 4) at both day 4 and day 10 postobstruction. Numbers
represent the mean signal log ratio, where 1 is equivalent to a twofold change in expression.
aColumns represent the mean of four comparisons ± standard deviation (SD) (the four comparisons are from straight and cross-comparisons of the duplicate chips at each time point).
bEST sequences which showed significant homology to the named genes by Blastn and Blastx searches on http://www.ncbi.nlm.nih.gov/blast
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Table 2. Genes whose expression is altered at day 4 but not day 10
post unilateral ureteral obstruction (UUO)
Mean signal log ratioaGenBank
ID Gene family Day 4 ± SD Day 10 ± SD
Cell growth and
differentiation
Y15163 Mrg1 protein 1.08 ± 0.17 NC
AF079528 IER5 (ler5) gene 1.28 ± 0.15 NC
U43084 Interferon-induced, 1.35 ± 0.93 NC
tetratricopeptide
repeats 1
U88908 Apoptosis inhibitor 1 3.05 ± 1.48 NC
M34896 Ecotropic viral 3.15 ± 0.31 NC
integration site 2
Cytokine and growth
factor
Al158810b Interferon alpha induced 1.40 ± 0.32 NC
11.5kD protein
U56819 MCP-1 receptor mRNA 4.58 ± 0.17 NC
NC is no change (Affymetrix software).
Affymetrix oligonucleotide gene expression analysis of obstructed kidneys
(N = 4) compared to contralateral control kidneys (N = 4) at both day 4 and
day 10 postobstruction. Numbers represent the mean signal log ratio, where 1 is
equivalent to a twofold change in expression.
aColumns represent the mean of four comparisons ± standard deviation (SD)
(the four comparisons are from straight and cross-comparisons of the duplicate
chips at each time point).
bEST sequences which showed significant homology to the named genes by
Blastn and Blastx searches on http://www.ncbi.nlm.nih.gov/blast
previously to be down-regulated immediately after UUO
and increased from day 5 onward [10]. This finding high-
lights the usefulness of our technique in dissecting the
global gene expression changes occurring during progres-
sion of tubulointerstitial fibrosis.
To validate our model and to verify the expression pat-
terns obtained from the microarray screen, we investi-
gated the expression of five genes: TGF-b1, collagen type
I a1, EGF, transgelin, and fisp-12/CTGF, using semiquan-
titative RT-PCR and quantitative real-time PCR. Since
the association of TGF-b1 and collagen Ia1 with tubu-
lointerstitial fibrosis has been extensively documented,
we validated our system by monitoring the expression of
these genes. Up-regulation of TGF-b1 was determined
to be 2.15 ± 0.87 (day 4) and 3.95 ± 0.35 (day 10) (signal
log ratio ± SD) by microarray analysis (Table 1) and was
assessed at 4.8- and 2.6-fold compared to respective con-
tralateral levels at days 4 and 10 post-UUO, respectively,
using real-time PCR (Fig. 1A). Collagen Ia1 mRNA lev-
els were also up-regulated, 1.93 ± 0.1 (day 4) and 2.10 ±
0.28 (day 10) (signal to log ratio ± SD) and this up-
regulation was confirmed by RT-PCR analysis (Fig. 1B)
with relative mRNA levels increasing from 0.22 ± 0.01
to 1.35 ± 0.10 at day 4 (P < 0.01) and from 0.29 ± 0.08
to 3.4 ± 0.19 at day 10 post-UUO (P < 0.001) (Fig. 1B
and C). EGF was down-regulated −3.03 ± 0.05 by day
4 and −5.00 ± 0.14 by day 10 (signal log ratio) and the
relative mRNA levels as determined by RT-PCR analysis
decreased from 2.0 ± 0.53 to 0.63 ± 0.09 at day 4 and from
3.32 ± 0.44 to 0.23 ± 0.05 by day 10 (P < 0.001) (Fig. 1B
Table 3. Genes whose expression is altered at day 10 but not day 4
post unilateral ureteral obstruction (UUO)
Mean signal log ratioaGenBank
ID Gene family Day 4 ± SD Day 10 ± SD
Extracellular matrix and
cytoskeletal
X62622 Tissue inhibitor of
metalloproteinase 2
NC 1.20 ± 0.14
X75285 Fibulin 2 NC 1.55 ± 0.07
Z38110 PMP22 peripheral myelin
protein
NC 1.05 ± 0.07
X70853 BM-90/Fibulin NC 1.05 ± 0.35
Y17808 A6 related protein NC 1.50 ± 0.00
AB009993 Collagen a1(V) NC 2.25 ± 0.78
M33960 Plasminogen activator
inhibitor (PAI-1) mRNA
NC 2.25 ± 0.64
L36244 Matrix metalloproteinase 7 NC 5.70 ± 0.71
M82831 Macrophage
metalloelastase
NC 3.45 ± 0.49
J04181 A-X actin mRNA NC −1.90 ± 1.41
Cell growth and differentiation
Y09864 Type I interferon receptor,
IFNaR2b
NC 1.30 ± 0.14
Y13089 Caspase-11 NC 3.45 ± 1.77
Cytokine and growth
factor
X81580 Insulin-like growth factor
binding protein 2
NC 1.00 ± 0.28
D25540 TGF-beta type I receptor NC 1.45 ± 0.21
M64849 Platelet derived growth
factor, B polypeptide
NC 1.60 ± 0.28
AF004874 Latent TGF beta binding
protein 2
NC 1.35 ± 0.21
D16250 BMP2 and BMP4 receptor NC 1.55 ± 0.35
M21952 Macrophage
colony-stimulating factor
(4 kb)
NC 1.80 ± 0.71
U27267 Small inducible cytokine B
subfamily, member 5
NC 3.45 ± 1.06
AB023418 Monocyte chemoattractant
protein-2 precursor
NC 4.25 ± 0.07
NC is no change (Affymetrix software).
Affymetrix oligonucleotide gene expression analysis of obstructed kidneys
(N = 4) compared to contralateral control kidneys (N = 4) at both day 4 and
day 10 postobstruction. Numbers represent the mean signal log ratio, where 1 is
equivalent to a twofold change in expression.
aColumns represent the mean of four comparisons ± standard deviation (SD)
(the four comparisons are from straight and cross-comparisons of the duplicate
chips at each time point).
and C). Transgelin was up-regulated by 1.6 ± 0.12 and
1.75 ± 0.21 (signal log ratio ± SD) at days 4 and 10 post-
UUO, respectively. Again this regulation was confirmed
by RT-PCR with the relative mRNA levels increasing
from 0.20 ± 0.01 to 1.61 ± 0.4 (P < 0.01) at day 4 and
from 0.74 ± 0.03 to 3.61 ± 0.33 at day 10 (P < 0.001)
(Fig. 1B and C).
Fisp-12 was up-regulated by 1.1 ± 0.24 (day 4) and
1.45 ± 0.07 (day 10) (signal log ratio ± SD) in the microar-
ray analysis, by quantitative real-time PCR, the relative
abundance of fisp-12 was calculated at 1.9- and 2.6-fold,
respectively (Fig. 1A). RT-PCR analysis confirmed these
findings with relative quantities detected at 0.97 ± 0.02
to 4.05 ± 0.11 (P < 0.001) at day 4 and from 1.57 ± 0.06
to 2.95 ± 0.12 at day 10 (P < 0.01) (Fig. 1B and C).
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Fig. 1. Validation of oligonucleotide mi-
croarray analysis by quantitiative polymerase
chain reaction (PCR) and reverse transcrip-
tion (RT)-PCR highlighting the induction of
fibroblast-inducible secreted protein (fisp-12),
the murine homologue of human connective
tissue growth factor (CTGF). (A) Quantita-
tive real-time PCR for transforming growth
factor-b1 (TGF-b1) and fisp-12 at days 4 and
10 postobstruction (N = 4, pooled mRNA)
confirming the gene expression changes ob-
served on the oligonucleotide microarray.
Results are displayed as relative quantities
normalized to respective 18S rRNA levels.
Symbols are: () contralateral control kidney;
() unilateral ureteral obstructed kidney. (B)
RT-PCR of contralateral control (CTL) (N =
4 for day 4 and day 10) and unilateral ureteral
obstructed (UUO) (N = 3 for day 4 and N = 4
for day 10) kidneys for genes identified in the
microarray screen as differentially regulated
in response to UUO. Negative RT-PCR reac-
tions (-ve) were performed on RNA pooled
for each time point and reverse transcribed in
the absence of reverse trancriptase enzyme.
(C) Densitometric analysis of the RT-PCR
data from (B), each transcript is normalized
to its respective 18S rRNA transcript level.
Mean values ± SEM are shown. ∗P < 0.001
and ∗∗P < 0.01 compared to respective con-
tralateral kidneys.
EMT of tubule epithelial cells by TGF-b 1 and EGF
induces fisp-12, collagen XVIIIa 1, SSeCKS, and SPARC
mRNA expression
Increased numbers of fibroblasts within the interstitial
area are characteristic of tubulointerstitial fibrosis asso-
ciated with ESRD [18]. TGF-b1 has been implicated in
this process by stimulating EMT of tubule epithelial cells
toward a fibroblast-like phenotype [18–20]. Stimulation
of proximal tubular epithelial MCT cells with 3 ng/mL
or 10 ng/mL TGF-b1 induced a significant increase in
CTGF mRNA levels by 24 hours to 1.2-fold (P <0.05) and
1.3-fold (P < 0.001), respectively, compared to vehicle-
treated cells as assessed by quantitative real-time PCR
(Fig. 2A).
To assess the influence of EMT on fisp-12 levels,
we stimulated MCTs cells with 3 ng/mL TGF-b1 and
10 ng/mL EGF for 72 hours to induce EMT [19]. The
combination of TGF-b1 and EGF has been reported to
enhance the process of EMT in MCT cells [19], there-
fore we used this combination to maximize the num-
ber of transitioned cells. During this process, epithelial
cells lose their cell-cell contacts, elongate to display a fi-
broblastic appearance (Fig. 2B), and express increased
levels of fsp-1. Analysis of RT-PCR products, using den-
sitometry, for fsp-1 mRNA confirmed the induction of
this transcript from 1.00 ± 0.17 for vehicle-treated cells,
relative to GAPDH levels, to 1.93 ± 0.21 for transi-
tioned cells (P < 0.005) (Fig. 2C). Analysis of fisp-12
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Fig. 2. Epithelial to mesenchymal transition (EMT) of tubular epithe-
lial cells in vitro is associated with the induction of fibroblast-inducible
secreted protein (fisp-12) expression. (A) Quantitative real-time poly-
merase chain reaction (PCR) detection of increased fisp-12 mRNA ex-
pression following exposure of MCT cells to 3 ng/mL and 10 ng/mL
transforming growth factor-b1 (TGF-b1) for 24 hours in vitro (N = 3).
∗P < 0.05; ∗∗P < 0.001 vs. vehicle-treated cells. Symbols are: () vehicle-
treated; () TGF-b1-treated. (B) Morphologic evidence of EMT fol-
lowing exposure of murine proximal tubular (MCT) cells to 3 ng/mL
TGF-b1 and 10 ng/mL epidermal growth factor (EGF) for 72 hours (ar-
rows show elongated cells, arrowheads show loss of cell to cell contacts)
(magnification ×400). (C) Relative abundance of fibroblast specific
protein-1 (fsp-1), and fisp-12 mRNA in vehicle-treated () and
EMT-stimulated () MCT cells. Results are derived from densitomet-
ric analysis of reverse transcription (RT)-PCR products from three
independent experiments, each performed in triplicate, normalized
to respective glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
housekeeping gene levels. ∗P < 0.005 vs. vehicle-treated cells.
in vehicle-treated and transitioned MCTs (normalized
to their respective GAPDH levels) revealed a signifi-
cant increase in the mRNA level of this transcript during
transition, from 1.00 ± 0.05 to 5.47 ± 0.23 (P < 0.005)
(Fig. 2C).
We analyzed three other putative profibrogenic genes,
which were identified in the UUO microarray screen, dur-
ing transition of tubule epithelial cells. Collagen XVIIIa1,
SPARC, and SSeCKS were up-regulated at both days
4 and 10 post-UUO (Table 1), these changes in gene
expression were confirmed by RT-PCR (Fig. 3A). Col-
lagen XVIIIa1 and SSeCKS mRNA levels were nonde-
tectable in contralateral kidneys but were significantly
increased in the obstructed kidney (P < 0.05) (Fig. 3B).
SPARC mRNA levels were slightly elevated above con-
tralateral at day 4 but were significantly increased by day
10 from 1.26 ± 0.46 to 2.66 ± 0.27 (P < 0.05) (Fig. 3C).
Transcript levels for all three genes were monitored
during transition of MCT cells. mRNA levels for colla-
gen XVIIIa1, SPARC, and SSeCKS were significantly
induced in transitioned cells (Fig. 3C and D), from
0.74 ± 0.02 in vehicle-treated cells to 1.78 ± 0.27 (P <
0.02 compared to vehicle) for collagen XVIIIa1, from
1.05 ± 0.06 to 2.13 ± 0.49 (P ≤ 0.005 compared to ve-
hicle) for SPARC, and from 0.44 ± 0.08 to 2.29 ± 0.33
(P ≤ 0.005) for SSeCKS.
DISCUSSION
In the current study, oligonucleotide microarray anal-
ysis of murine UUO kidneys led to the identification of
changes in the expression of 1091 genes during progres-
sion to tubulointerstitial fibrosis. Functional classification
revealed marked alterations in the expression of genes
involved with extracellular matrix, cytoskeletal reorgan-
isation, signaling pathways, and cell cycle progression
and regulation. Initially in obstructed kidneys, there is an
influx of mononuclear cells, which secrete cytokines and
growth factors, which act on the renal interstitium to pro-
mote the development of fibrosis [22]. By analyzing gene
expression at an early and a later time point, day 4 and
day 10 postobstruction, we hoped to identify changes in
gene expression, which reflect the temporal changes in
the morphology of obstructed kidneys [13, 23]. Interest-
ingly, we found that the majority of genes which displayed
an alteration in expression level at day 4 were further
altered by day 10, suggesting that persistent rather than
transient changes in gene expression are important in the
development of tubulointerstitial fibrosis.
Genes encoding extracellular matrix/cytoskeletal
molecules underwent major transcriptional alterations
during UUO, 64 genes were identified which were sig-
nificantly up-regulated by days 4 and 10 post-UUO
compared to the contralateral kidney reflecting the mor-
phologic changes observed in fibrotic kidneys. Signif-
icantly increased transcript levels for these molecules,
including collagens I, III, IV, V, VI, XV, XVIII, nidogen,
tenascin C, and cadherin among others, were observed as
early as 4 days after obstruction, highlighting the impor-
tance of differential regulation of these genes in the initial
stages of fibrosis. Of note, transcript levels for collagens
I and III showed greater increases than collagen IV, con-
firming previous findings for these molecules. Transcript
levels for molecules which regulate the turnover of these
extracellular matrix proteins were also differentially
2088 Higgins et al: Microarrays identify therapeutic targets in UUO
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Fig. 3. mRNA levels for collagen XVIIIa 1,
src-suppressed C-kinase substrate (SSeCKS),
and secreted protein acidic and rich in cys-
teine (SPARC), are increased in response to
unilateral ureteral obstruction (UUO) and
during epithelial to mesenchymal transition
(EMT) of tubular epithelial cells. (A) Reverse
transcription-polymerase chain reaction (RT-
PCR) analysis of contralateral control (CTL)
(N = 4 for day 4 and day 10) and obstructed
(UUO) (N = 3 for day 4 and N = 4 for day 10)
kidneys at days 4 and 10 confirming the data
obtained in the oligonucleotide microarray
screen. (B) Densitometric analysis of the RT-
PCR data in (A), each transcript is normalized
to its respective 18S rRNA transcript level,
mean values ± SEM are shown, ∗P < 0.05.
(C) RT-PCR analysis of mRNA transcripts for
collagen XVIIIa1, SSeCKS, and SPARC in
vehicle-treated and EMT-stimulated murine
proximal tubular (MCT) cells. Three inde-
pendent experiments were perfomed, each
in triplicate. A representative experiment is
shown. (D) Densitometric analysis of the
RT-PCR products. Symbols are: () vehicle-
treated; () EMT-stimulated. Results are de-
rived from three independent experiments,
each performed in triplicate, normalized to
respective glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) housekeeping gene lev-
els (N = 3). ∗P < 0.02; ∗∗P ≤ 0.005.
regulated with tissue inhibitors of metalloproteinase
(TIMP-3) down-regulated at both days 4 and 10 and
TIMP-2 only showing up-regulation by day 10 and not
by day 4. Interestingly, mRNA levels for matrix metallo-
proteinase (MMP-7) were not significantly changed dur-
ing the early stages of renal fibrosis but were significantly
increased by day 10 (Table 2). MMP-7 levels have been
found to be increased in pulmonary fibrosis and mice defi-
cient for MMP-7 were protected from bleomycin-induced
pulmonary fibrosis [24]. These findings serve to validate
our model and highlight the importance of differential
gene expression which underlies the progression of tubu-
lointerstitial fibrosis.
Another important gene family which showed marked
alteration with UUO included transcripts encoding for
molecules involved with cell cycle regulation, including
cytokines and growth factors. As expected, EGF was
down-regulated in response to UUO along with insulin-
like growth factor binding proteins, this may result in an
environment conducive to the loss of epithelial growth
signals, leading to a reduction in epithelial cell survival
and contributing to the loss of epithelial integrity.
Changes in tissue mRNA levels in vivo can reflect both
changes in the transcriptome of resident tissue cells and
the presence of infiltrating cells. Whereas the latter are
relevant to studies pertaining to molecular diagnostics,
they may confound interpretation of studies addressing
the regulation of gene expression in resident cells. To
circumvent this difficulty, we complemented our in vivo
microarray analysis in the present study with assessment
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of the expression of a cohort of potentially profibrogenic
genes in vitro in response to TGF-b1 stimulation and sub-
sequent EMT.
TGF-b1 is an important cytokine within the kidney and
has been implicated in portraying a pathologic role in
renal disease [25–27]. The pleiotropic actions of TGF-
b1 in the kidney include suppression of mononuclear
cell proliferation, induction of other cytokines [25], and
induction of EMT, limiting its attractiveness as a ther-
apeutic target. Blockade of fisp-12/CTGF may offer an
alternative therapeutic strategy. TGF-b1 has been shown
to induce EMT, which results in alterations of cell mor-
phology to a more “fibroblast-like” phenotype and func-
tional profile [19, 28]. EMT is becoming more widely
associated with tubulointerstitial fibrosis and has been
reported in a number of renal diseases, which include
fibrotic lesions associated with ESRD. EMT occurs in
response to cytokines such as TGF-b1, EGF, fibroblast
growth factor 2 (FGF-2), interleukin-1 (IL-1), and com-
binations of cytokines can induce EMT to a greater ex-
tent [18, 29, 30]. Here we describe the induction of fisp-12,
the murine homologue of CTGF, during UUO showing
that this gene functions during fibrosis. We observed that
TGF-b1 stimulation alone induced a transient twofold
increase in CTGF mRNA levels which declines after
24 hours of treatment (data not shown). However, we ob-
served a fivefold increase in CTGF mRNA levels when
MCT cells were induced to undergo EMT, revealing that
a sustained increase in CTGF production occurs during
the cytoskeletal remodeling triggered during EMT. This
suggests that CTGF may play a role in the morphologic
changes observed during EMT and therefore warrants
further investigation. Since remodeling of tubular epithe-
lium is a critical factor in tissue fibrosis leading to signif-
icant loss of renal function, this observation for CTGF
may uncover a novel mechanism for controlling tubule
integrity during renal fibrosis.
In this report, we have demonstrated that fisp-12
expression is promoted by TGF-b1 in renal proximal
tubular cells and is induced during the process of EMT
in response to this cytokine. Recently, CTGF has been
shown to increase the production of collagen I in renal
fibroblasts showing that it too can induce alterations to
the extracellular matrix and contribute to the overall
change in extracellular matrix composition as seen with
tubulointerstitial fibrosis [15].
Among the genes up-regulated in UUO reported in
this paper were collagen XVIIIa1, SPARC, and SSeCKS.
We focused on these genes since we believe they have a
potential role in the regulation of cell morphology, the al-
teration of which underlies the tubular changes observed
in UUO. Up-regulation of these genes was confirmed
within UUO and furthermore we have demonstrated
their up-regulation during EMT. Collagen XVIIIa1,
also known as endostatin; an angiogenesis inhibitor,
has been demonstrated to have a pathogenic role in
chronic liver fibrosis [32]. It is expressed in mouse base-
ment membranes, vascular smooth muscle cells and ep-
ithelia and displays high expression within the liver.
Activated stellate cells and myofibroblasts in human
fibrotic livers were shown to increase their levels of
collagen XVIIIa1, resulting in its association with base-
ment membrane remodeling [33]. This correlates with our
finding of increased expression of collagen XVIIIa1 in
epithelial cells undergoing EMT, which display a stellate,
fibroblast-phenotype.
SPARC is a secreted glycoprotein that affects cellular
interactions with matrix proteins [34]. It has been im-
plicated in extracellular matrix deposition and has been
shown to bind collagen types I, III, IV, V, and VIII [35],
all of which are up-regulated during UUO. SPARC aug-
ments the production of PAI-1 and the MMPs: collage-
nase, gelatinase, and stromolysin [36]. Its expression is
increased by TGF-b1, IL-1, and colony stimulating factor
1 (CSF-1), and has been detected in interstitial a-smooth
muscle actin(a-SMA)-positive fibroblasts [35]. SPARC
colocalizes with collagen type I–expressing cells in exper-
imental models in which tubulointerstitial fibrosis occurs
such as passive Heymann nephritis (PHN), cyclosporine
A nephropathy, remnant kidney, and angiotensin II in-
fusion model [34]. SPARC has been shown to inhibit
proliferation of endothelial cells, fibroblasts, and smooth
muscle cells and its expression correlates with the resolu-
tion of interstitial cell proliferation at day 15 of PHN [34].
In PHN, glomerular epithelial cells and spindle-shaped
interstitial cells, in areas of extracellular matrix expan-
sion, were found to express SPARC.
SSeCKS was originally isolated as an src-suppressed
negative mitogenic regulator in fibroblasts [37]. SSeCKS
associates with cyclin D1 and sequesters it in the cyto-
plasm, inhibiting its translocation to the nucleus. In re-
sponse to mitogenic growth factors, SSeCKS is rapidly
phosphorylated by extracellular signal-regulated protein
kinase (ERK-2), translocates to the perinucleus, loses
its binding capacity for cyclin D1, which enables entry
of cyclin D1 to the nucleus and the initiation of subse-
quent molecular events for the progression to S phase
and cell proliferation [38]. In this manner, SSeCKS acts
as a scaffolding protein linking signals between extra-
cellular mitogens and downstream ERK-kinase signaling
pathways such as protein kinase A (PKA) and protein ki-
nase C (PKC). Expression of SSeCKS was abundant in
human and rodent mesangial cells and glomerular pari-
etal cells and was reported as undetectable in renal tubu-
lar epithelia [39]. This was surprising as we were able to
detect SSeCKS mRNA in renal proximal tubule epithe-
lial cells and found an increase in mRNA levels in cells
undergoing EMT. It has been suggested that SSeCKS
functions to maintain an elongated cell phenotype with
stellate projections [39] and this would correspond to
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our finding of increased SSeCKS mRNA in tubule ep-
ithelial cells undergoing transition, which display a stel-
late fibroblast phenotype. Our findings suggest a role
for SSeCKS as a downstream mediator of TGF-b1–
controlled actin-based cytoskeletal architecture.
A recent paper by Zavadil et al [31] describes the
molecular alterations induced by TGF-b1 on human
keratinocytes. Comparison of the genes identified in the
TGF-b1 microarray analysis yields numerous similari-
ties to the gene expression changes identified with our
microarray data published here. Extracellular matrix–
related molecules, which were positively regulated by
TGF-b1 treatment, including transgelin, tenascin C,
laminin, tubulin, and MMP-14, also displayed up-
regulation in our microarray screen. TIMP-3 was down-
regulated by TGF-b1 treatment and we also observed
down-regulation of this molecule during UUO. This fur-
ther highlights the important role that TGF-b1 plays in
renal fibrosis and strengthens the requirement for the
identification of a molecular target that mediates the
fibrogenic effects of TGF-b1. We propose that CTGF,
SPARC, SSeCKS, and collagen XVIIIa1 may represent
such therapeutic targets.
Zavadil et al [31] conclude that TGF-b1 regulates (1)
defined functional classes of molecules involved in ep-
ithelial plasticity and in the differentiation of transitional
progenitor cells and (2) cohorts of genes involved in re-
modeling of the actin cytoskeleton and actin stress fiber
formation. We conclude that genes involved in transition
of one cell phenotype to another are important during
the progression of tubulointerstitial fibrosis and that al-
terations in the expression of genes controlling these phe-
notypic changes is critical to the development of a fibrotic
environment.
CONCLUSION
We report alterations of gene expression during the de-
velopment of tubulointerstitial fibrosis. EMT results in
the up-regulation of a number of genes whose mRNA
levels are also increased during UUO, further high-
lighting the potential importance of this process dur-
ing the development of fibrosis within the interstitium.
Prominent among these molecules were several profi-
brogenic molecules, including fisp-12, collagen XVIIIa1,
SSeCKS, and SPARC. The further delineation of the
transcriptomic events underpinning renal fibrosis and of
the molecular and signaling pathways that regulate these
events should help unravel the complex mechanisms of
tubulointerstitial scarring and suggest new approaches to
the treatment of progressive renal disease.
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